Compare Marvell Technology Inc (MRVL) vs 10X Genomics Inc (TXG) Price & Performance

Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day but maintains strong technical momentum with bullish moving averages and key support at $267. The company shows impressive earnings beats in recent quarters with Q2 2026 EPS of $0.94 beating expectations, while analyst consensus remains overwhelmingly bullish with 84% buy ratings. Recent news highlights Marvell's AI chip growth potential, including a major Google partnership and raised 2028 revenue guidance to $18 billion.

Marvell presents compelling growth prospects driven by AI infrastructure demand and custom chip expansion, though elevated valuation ratios (P/E 90.95, P/S 25.77) warrant caution. Key risks include execution challenges in scaling custom silicon business and competitive pressures in the semiconductor sector. The $327.86 consensus price target suggests 19% upside potential from current levels.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.